Following a number of lawsuits filed over its transvaginal mesh products, device maker C.R. Bard’s profits dropped a massive $26 million in this year’s first quarter.
Based in Murray Hill, New Jersey. C.R. Bard exceeded Wall Street expectations with adjusted earnings, noted MassDevice.
Thousands of women were recipients of vaginal mesh devices that were implanted transvaginally. The devices have come under increased scrutiny in the last two years, especially since many recipients of these devices began experiencing complications related to their defects, including severe pain, erosion of the devices through the skin or tissue, serious infections, and the need for constant revision surgeries to either correct or remove the devices.
Five vaginal mesh multidistrict litigations in the U.S. District Court for the Southern District of West Virginia are scheduled to begin their first three-bellwether trials later this year. The bellwether’s involve different mesh manufacturers, including C.R. Bard.
Transvaginal mesh is used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). Complication reports, mounting litigation, and concerns over the lack of clinical testing associated with these devices have raised questions about the devices’ safety. Approved through fast-track process known as the 510(k), a formal review for safety and efficacy was neither required nor performed. Because the 510(k) route has been used to gain U.S. Food and Drug Administration (FDA) clearance for other controversial products, such as metal-on-metal hip implants, the process has drawn increasing criticism.
We’ve long written that transvaginal mesh allegedly has a risk of erosion, in which it travels through the body’s tissues. In some cases, the device can become embedded in inappropriate areas and multiple surgeries are required to remove it. Sadly, in many cases, erosion is so significant and widespread that the mesh cannot ever be completely removed. Lawsuits allege that vaginal mesh device makers knew this, yet failed to warn consumers.
Last July, the FDA warned that, contrary to what was initially believed, complications associated with transvaginal mesh are, in fact, “not rare.” The agency also stated that no substantial evidence exists that transvaginal mesh offers significant benefits over non-mesh methods for treating POP and may pose more risks. The FDA has asked 33 manufacturers to conduct post-market safety studies to assess the risk of transvaginal mesh on organ damage and other health issues. Also, according to an FDA Safety Communication on the matter, the most commonly reported complications associated with transvaginal mesh include: Mesh erosion through the vagina (exposure, extrusion, protrusion), pain, infection, bleeding, pain during sexual intercourse (dyspareunia), organ perforation, and urinary problems.
A multidistrict litigation allows lawsuits associated with a particular product and alleging similar injuries to be coordinated under one judge for pretrial litigation to avoid duplicative discovery and inconsistent rulings and to conserve the resources of the parties, witnesses, and the court. When lawsuits are consolidated as a multidistrict litigation, each retains its own identity. If the MDL process does not resolve the cases, they are transferred back to the court where they originated for trial. Initial cases are known as so-called “bellwether trials,” and enable involved parties to better understand and predict how future cases will turn out and if their cases should be negotiated for an out-of-court settlement.